SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Sigilon Therapeutics, Inc. SGTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Sigilon Therapeutics, Inc. (SGTX) is a Biotechnology company in the Healthcare sector, currently trading at $22.47. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $13M, +0.4%/yr average growth. Net income is $43M (loss), growing at -7.1%/yr. Net profit margin is -335.7% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $28M against $39M equity (Debt-to-Equity (D/E) ratio 0.72, moderate). Current ratio is 2.4 (strong liquidity). Debt-to-assets is 32.2%. Total assets: $87M.

Analyst outlook: 2 / 5 analysts rate SGTX as buy (40%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 30/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 46/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

SGTX SharesGrow Score Overview

31/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 30/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 46/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SGTX

No analyst coverage available for this stock.

SGTX: +0.4%/yr revenue is, -7.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet SGTX: Debt-to-Equity (D/E) ratio 0.72 (moderate), Current ratio is 2.4 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

SGTX: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 5 analysts rate SGTX as buy (40%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

SGTX: Net profit margin is -335.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range3.77-28.0

Volume81.88K

Avg Volume (30D)120.68K

Market Cap$56.22M

Beta (1Y)4.11

Share Statistics

EPS (TTM)-1.34

Shares Outstanding$32.41M

IPO Date2020-12-04

Employees62

CEORogerio Vivaldi Coelho MBA

Financial Highlights & Ratios

Revenue (TTM)$12.94M

Gross Profit$12.94M

EBITDA$-41.27M

Net Income$-43.46M

Operating Income$-43.67M

Total Cash$69.63M

Total Debt$28.06M

Net Debt$-14.01M

Total Assets$87.28M

Price / Earnings (P/E)-16.8

Price / Sales (P/S)4.34

Analyst Forecast

Rating ConsensusHold

Analysts Covering5

Buy 40% Hold 60% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS82657L1070

Price Chart

SGTX

Sigilon Therapeutics, Inc. ↗ · NASDAQ Global Select

Healthcare • Biotechnology

3.77 52WK RANGE 28.00

People Also View

Unicycive Therapeutics, Inc.

Landos Biopharma, Inc.

NovaBay Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc.

Angion Biomedica Corp.

Apollomics, Inc.

Phio Pharmaceuticals Corp.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message